By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



205 East 42nd Street, 16th Floor

New York  New York  33324  U.S.A.
Phone: 973-242-0005 Fax: n/a


Company News
Neurotrope (NTRP) Provides Business Update And Reports Second Quarter 2017 Financial Results 8/9/2017 12:43:41 PM
Neurotrope (NTRP) Presents Phase II Data Assessing Bryostatin-1 In Moderate-To-Severe Alzheimer's Patients At AAIC 2017 7/19/2017 9:32:15 AM
Neurotrope (NTRP) To Present Bryostatin Phase 2 Data In An Oral Presentation At AAIC 2017 Meeting 6/30/2017 9:18:24 AM
Is This Fake News? Neurotrope (NTRP) Alzheimer's Release Takes Weird Spin 5/5/2017 6:16:48 AM
Neurotrope (NTRP) Craters As Alzheimer's Drug Fails To Impress In Mid-Stage Study 5/1/2017 6:26:41 AM
Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017 4/28/2017 9:04:37 AM
Neurotrope Announces Approval For Listing On The NASDAQ Capital Market 3/27/2017 8:36:34 AM
Neurotrope Concludes Patient Dosing And Monitoring In Its 148 Patient Phase II Clinical Trial Of Moderate To Severe Alzheimer's Dementia 2/28/2017 6:48:28 AM
Neurotrope Completes Licensing Agreement For Accelerated Synthesis Of Alzheimer's Drug Bryostatin-1 1/30/2017 6:46:03 AM
Neurotrope Release: Biotech Announces Reverse Split Of Common Stock In Preparation For NASDAQ Uplisting 1/12/2017 6:45:41 AM